reference/36623492

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36623492

Outgoing Links

Predicate	Object
contentType	Randomized Controlled Trial\|Clinical Trial, Phase III\|Journal Article
issn	0169-5002
pageRange	107455-
publicationName	Lung cancer (Amsterdam, Netherlands)
startingPage	107455
bibliographicCitation	Cheng Y, Wu L, Huang D, Wang Q, Fan Y, Zhang X, Fan H, Yao W, Liu B, Yu G, Pan Y, Xu F, He Z, Dong X, Ma R, Min X, Ge X, Chen H, Liu Q, Hu Y, Liu Y, Yang C, Yang Y, Li X, Zhou L. Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES). Lung Cancer. 2024 Feb;188():107455. doi: 10.1016/j.lungcan.2023.107455. PMID: 38224653.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16ba76a90284ff4c24c9db6b97202dbd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4beac4814d7987e9a3f3e3ce9b2d7c84 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0742974ce200cfaefa3249b9c535ae55 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3323c305a4c6673e61117b72826ab991 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ac255629f8dd2eade5fb20b09801b62e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_363fa5dce705ab84f4a4f2098fb736ca http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9ba2575028fb571027cb588bf7f1d9db http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d7626e40cbedb01b2b0636498b0d7cd9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_67d92495ba50fab05c4627c40d7f8ab0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1e0b760c7e9775e93d11b1f03cad9e8b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_41c4c39a921ecf4e5e8b07debeafe53b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ac915829145d6e5725cf61f33b8829f4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_45c18cc694ba9b64ae951e30122a9f1a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76c5bb515c2faa08330264cd1a1de15c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cd39ebae917e061fe6e2dc558dc6b600 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2ae014e357bf0f97737849baba6765f5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-9908-597X http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c3a7fb9dbc0e9ad81d888eba68656d88 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6383198353970953bb6d952516e8fbb5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2332673726c7ceaf97f68bcec14af843 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2511743cd24a2b2762496e249994b2de http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a6d548f4691c00a7192201ce7e65db26 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b44d33b4c48221fcec49f9d916366def http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8037cd33d5b8203dda63e72a378bf2c6
date	202402
identifier	https://pubmed.ncbi.nlm.nih.gov/38224653 https://doi.org/10.1016/j.lungcan.2023.107455
isPartOf	https://portal.issn.org/resource/ISSN/0169-5002 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8534
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)
discusses	http://id.nlm.nih.gov/mesh/M0018260 http://id.nlm.nih.gov/mesh/M0024707 http://id.nlm.nih.gov/mesh/M0007930 http://id.nlm.nih.gov/mesh/M000735530 http://id.nlm.nih.gov/mesh/M0018276
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009503Q000139 http://id.nlm.nih.gov/mesh/D011743 http://id.nlm.nih.gov/mesh/D011758 http://id.nlm.nih.gov/mesh/D008175Q000473 http://id.nlm.nih.gov/mesh/D055752Q000473
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D002681 http://id.nlm.nih.gov/mesh/D016190 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D005047Q000627 http://id.nlm.nih.gov/mesh/D006801

Total number of triples: 56.